US20100240599A1 - Antioxidant constituents - Google Patents
Antioxidant constituents Download PDFInfo
- Publication number
- US20100240599A1 US20100240599A1 US12/753,481 US75348110A US2010240599A1 US 20100240599 A1 US20100240599 A1 US 20100240599A1 US 75348110 A US75348110 A US 75348110A US 2010240599 A1 US2010240599 A1 US 2010240599A1
- Authority
- US
- United States
- Prior art keywords
- antioxidant composition
- active oxygen
- antioxidant
- compound
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000003963 antioxidant agent Substances 0.000 title claims abstract description 133
- 230000003078 antioxidant effect Effects 0.000 title claims abstract description 113
- 239000000470 constituent Substances 0.000 title description 4
- 235000006708 antioxidants Nutrition 0.000 claims abstract description 130
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 100
- 239000000284 extract Substances 0.000 claims abstract description 98
- 239000001301 oxygen Substances 0.000 claims abstract description 98
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 98
- 239000000203 mixture Substances 0.000 claims abstract description 93
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 64
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims abstract description 24
- 150000001413 amino acids Chemical class 0.000 claims abstract description 24
- 239000011593 sulfur Substances 0.000 claims abstract description 24
- 229910052717 sulfur Inorganic materials 0.000 claims abstract description 24
- -1 caffeic acid analogue compound Chemical class 0.000 claims abstract description 20
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 20
- WQYVRQLZKVEZGA-UHFFFAOYSA-N hypochlorite Inorganic materials Cl[O-] WQYVRQLZKVEZGA-UHFFFAOYSA-N 0.000 claims abstract description 19
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 18
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 18
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 18
- 239000011718 vitamin C Substances 0.000 claims abstract description 18
- 235000021466 carotenoid Nutrition 0.000 claims abstract description 15
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims abstract description 14
- 108010016626 Dipeptides Proteins 0.000 claims abstract description 13
- 230000002000 scavenging effect Effects 0.000 claims abstract description 9
- 239000002211 L-ascorbic acid Substances 0.000 claims abstract description 8
- 235000000069 L-ascorbic acid Nutrition 0.000 claims abstract description 8
- 229960005070 ascorbic acid Drugs 0.000 claims abstract description 8
- 150000001875 compounds Chemical class 0.000 claims abstract description 8
- 229940044199 carnosine Drugs 0.000 claims description 43
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical class OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 claims description 30
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 claims description 24
- 235000001014 amino acid Nutrition 0.000 claims description 23
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 claims description 18
- 235000005487 catechin Nutrition 0.000 claims description 18
- 235000013305 food Nutrition 0.000 claims description 18
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims description 17
- 235000017471 coenzyme Q10 Nutrition 0.000 claims description 17
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 claims description 16
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims description 16
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 claims description 16
- 235000001785 ferulic acid Nutrition 0.000 claims description 16
- 229940114124 ferulic acid Drugs 0.000 claims description 16
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 claims description 16
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 claims description 16
- 235000013824 polyphenols Nutrition 0.000 claims description 15
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 13
- 241000894007 species Species 0.000 claims description 13
- 108010085443 Anserine Proteins 0.000 claims description 12
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 claims description 12
- 240000007124 Brassica oleracea Species 0.000 claims description 12
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 claims description 12
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 claims description 12
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 claims description 12
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 claims description 12
- 235000013793 astaxanthin Nutrition 0.000 claims description 12
- 239000001168 astaxanthin Substances 0.000 claims description 12
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 claims description 12
- 229940022405 astaxanthin Drugs 0.000 claims description 12
- 235000013734 beta-carotene Nutrition 0.000 claims description 12
- 239000011648 beta-carotene Substances 0.000 claims description 12
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 claims description 12
- 229960002747 betacarotene Drugs 0.000 claims description 12
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims description 12
- 235000005875 quercetin Nutrition 0.000 claims description 12
- 229960001285 quercetin Drugs 0.000 claims description 12
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 claims description 12
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 10
- 108010087806 Carnosine Proteins 0.000 claims description 10
- 241000196324 Embryophyta Species 0.000 claims description 10
- SLRNWACWRVGMKD-UHFFFAOYSA-N L-anserine Natural products CN1C=NC(CC(NC(=O)CCN)C(O)=O)=C1 SLRNWACWRVGMKD-UHFFFAOYSA-N 0.000 claims description 10
- 241000210053 Potentilla elegans Species 0.000 claims description 10
- MYYIAHXIVFADCU-QMMMGPOBSA-N anserine Chemical compound CN1C=NC=C1C[C@H](NC(=O)CC[NH3+])C([O-])=O MYYIAHXIVFADCU-QMMMGPOBSA-N 0.000 claims description 10
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 claims description 9
- 241000234282 Allium Species 0.000 claims description 9
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 claims description 9
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 claims description 9
- 108010024636 Glutathione Proteins 0.000 claims description 9
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 claims description 9
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 claims description 9
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 claims description 9
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 claims description 9
- 229940074393 chlorogenic acid Drugs 0.000 claims description 9
- 235000001368 chlorogenic acid Nutrition 0.000 claims description 9
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 claims description 9
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 claims description 9
- 240000000249 Morus alba Species 0.000 claims description 8
- 235000008708 Morus alba Nutrition 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 claims description 6
- 235000004883 caffeic acid Nutrition 0.000 claims description 6
- 229940074360 caffeic acid Drugs 0.000 claims description 6
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 claims description 6
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims description 5
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 5
- 229930003427 Vitamin E Natural products 0.000 claims description 5
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 5
- 229930182817 methionine Natural products 0.000 claims description 5
- 235000019165 vitamin E Nutrition 0.000 claims description 5
- 229940046009 vitamin E Drugs 0.000 claims description 5
- 239000011709 vitamin E Substances 0.000 claims description 5
- 241000251468 Actinopterygii Species 0.000 claims description 4
- XUHLIQGRKRUKPH-GCXOYZPQSA-N Alliin Natural products N[C@H](C[S@@](=O)CC=C)C(O)=O XUHLIQGRKRUKPH-GCXOYZPQSA-N 0.000 claims description 4
- 241000219198 Brassica Species 0.000 claims description 4
- XUHLIQGRKRUKPH-UHFFFAOYSA-N S-allyl-L-cysteine sulfoxide Natural products OC(=O)C(N)CS(=O)CC=C XUHLIQGRKRUKPH-UHFFFAOYSA-N 0.000 claims description 4
- XUHLIQGRKRUKPH-DYEAUMGKSA-N alliin Chemical compound OC(=O)[C@@H](N)C[S@@](=O)CC=C XUHLIQGRKRUKPH-DYEAUMGKSA-N 0.000 claims description 4
- 235000015295 alliin Nutrition 0.000 claims description 4
- 229950001002 cianidanol Drugs 0.000 claims description 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 4
- 235000018417 cysteine Nutrition 0.000 claims description 4
- 235000013372 meat Nutrition 0.000 claims description 4
- 241000195493 Cryptophyta Species 0.000 claims description 3
- 244000000626 Daucus carota Species 0.000 claims description 3
- 235000002767 Daucus carota Nutrition 0.000 claims description 3
- 244000269722 Thea sinensis Species 0.000 claims description 3
- 235000021307 Triticum Nutrition 0.000 claims description 3
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 claims description 2
- 241001105098 Angelica keiskei Species 0.000 claims description 2
- 235000003261 Artemisia vulgaris Nutrition 0.000 claims description 2
- 240000006891 Artemisia vulgaris Species 0.000 claims description 2
- 235000000832 Ayote Nutrition 0.000 claims description 2
- 235000011331 Brassica Nutrition 0.000 claims description 2
- 235000012905 Brassica oleracea var viridis Nutrition 0.000 claims description 2
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 claims description 2
- 240000004244 Cucurbita moschata Species 0.000 claims description 2
- 235000009854 Cucurbita moschata Nutrition 0.000 claims description 2
- 235000009804 Cucurbita pepo subsp pepo Nutrition 0.000 claims description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 2
- 235000004347 Perilla Nutrition 0.000 claims description 2
- 244000124853 Perilla frutescens Species 0.000 claims description 2
- 241000209504 Poaceae Species 0.000 claims description 2
- 229960004308 acetylcysteine Drugs 0.000 claims description 2
- 235000013985 cinnamic acid Nutrition 0.000 claims description 2
- 229930016911 cinnamic acid Natural products 0.000 claims description 2
- 229960002433 cysteine Drugs 0.000 claims description 2
- 229960004452 methionine Drugs 0.000 claims description 2
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 claims description 2
- 235000015136 pumpkin Nutrition 0.000 claims description 2
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 claims description 2
- 229940035936 ubiquinone Drugs 0.000 claims description 2
- 244000098338 Triticum aestivum Species 0.000 claims 1
- 125000004403 catechin group Chemical group 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 38
- 241001465754 Metazoa Species 0.000 abstract description 10
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 abstract description 6
- CMFNMSMUKZHDEY-UHFFFAOYSA-N peroxynitrous acid Chemical compound OON=O CMFNMSMUKZHDEY-UHFFFAOYSA-N 0.000 abstract description 4
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 abstract 1
- 235000019187 sodium-L-ascorbate Nutrition 0.000 abstract 1
- 239000011755 sodium-L-ascorbate Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 description 41
- 239000008280 blood Substances 0.000 description 41
- NHYCGSASNAIGLD-UHFFFAOYSA-N Chlorine monoxide Chemical compound Cl[O] NHYCGSASNAIGLD-UHFFFAOYSA-N 0.000 description 40
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 36
- 241000287828 Gallus gallus Species 0.000 description 31
- 239000002516 radical scavenger Substances 0.000 description 26
- 230000002401 inhibitory effect Effects 0.000 description 24
- 238000010525 oxidative degradation reaction Methods 0.000 description 22
- 235000012000 cholesterol Nutrition 0.000 description 18
- 201000010099 disease Diseases 0.000 description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 18
- 230000015556 catabolic process Effects 0.000 description 17
- 238000006731 degradation reaction Methods 0.000 description 17
- 239000004615 ingredient Substances 0.000 description 17
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 16
- 239000000843 powder Substances 0.000 description 16
- 241000282414 Homo sapiens Species 0.000 description 15
- 230000006378 damage Effects 0.000 description 15
- 230000032683 aging Effects 0.000 description 13
- 150000001765 catechin Chemical class 0.000 description 13
- 210000003743 erythrocyte Anatomy 0.000 description 13
- 240000007594 Oryza sativa Species 0.000 description 12
- 235000007164 Oryza sativa Nutrition 0.000 description 12
- 150000008442 polyphenolic compounds Chemical class 0.000 description 12
- 230000003389 potentiating effect Effects 0.000 description 12
- 235000009566 rice Nutrition 0.000 description 12
- 241000972773 Aulopiformes Species 0.000 description 11
- 235000019515 salmon Nutrition 0.000 description 11
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 10
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 description 10
- 235000001169 Brassica oleracea var oleracea Nutrition 0.000 description 10
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 10
- 229940030275 epigallocatechin gallate Drugs 0.000 description 10
- 241001668545 Pascopyrum Species 0.000 description 9
- 230000009471 action Effects 0.000 description 9
- 150000001747 carotenoids Chemical class 0.000 description 9
- 206010012601 diabetes mellitus Diseases 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 235000012754 curcumin Nutrition 0.000 description 8
- 239000004148 curcumin Substances 0.000 description 8
- 229940109262 curcumin Drugs 0.000 description 8
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 7
- 108010058846 Ovalbumin Proteins 0.000 description 7
- 230000007423 decrease Effects 0.000 description 7
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 229940092253 ovalbumin Drugs 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 238000010521 absorption reaction Methods 0.000 description 6
- 210000000265 leukocyte Anatomy 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 229940072113 onion extract Drugs 0.000 description 6
- 230000002797 proteolythic effect Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 235000005979 Citrus limon Nutrition 0.000 description 5
- 244000131522 Citrus pyriformis Species 0.000 description 5
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 239000003925 fat Substances 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 4
- 238000008214 LDL Cholesterol Methods 0.000 description 4
- 240000008042 Zea mays Species 0.000 description 4
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 4
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 4
- 235000005822 corn Nutrition 0.000 description 4
- XVOYSCVBGLVSOL-UHFFFAOYSA-N cysteic acid Chemical compound OC(=O)C(N)CS(O)(=O)=O XVOYSCVBGLVSOL-UHFFFAOYSA-N 0.000 description 4
- 235000013373 food additive Nutrition 0.000 description 4
- 239000002778 food additive Substances 0.000 description 4
- 235000020688 green tea extract Nutrition 0.000 description 4
- 229940094952 green tea extract Drugs 0.000 description 4
- 230000009931 harmful effect Effects 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 235000014347 soups Nutrition 0.000 description 4
- 238000003809 water extraction Methods 0.000 description 4
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 3
- 235000004936 Bromus mango Nutrition 0.000 description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 240000007228 Mangifera indica Species 0.000 description 3
- 235000014826 Mangifera indica Nutrition 0.000 description 3
- 235000009184 Spondias indica Nutrition 0.000 description 3
- 229940008396 carrot extract Drugs 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 229910001882 dioxygen Inorganic materials 0.000 description 3
- 235000019688 fish Nutrition 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 235000014058 juice drink Nutrition 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000002075 main ingredient Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 230000036542 oxidative stress Effects 0.000 description 3
- 235000015277 pork Nutrition 0.000 description 3
- 230000017854 proteolysis Effects 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000001694 spray drying Methods 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 240000000560 Citrus x paradisi Species 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 241000277277 Oncorhynchus nerka Species 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- 241000209140 Triticum Species 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000000254 damaging effect Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 230000006806 disease prevention Effects 0.000 description 2
- 230000037149 energy metabolism Effects 0.000 description 2
- 235000012041 food component Nutrition 0.000 description 2
- 239000005417 food ingredient Substances 0.000 description 2
- 235000011194 food seasoning agent Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 108091005995 glycated hemoglobin Proteins 0.000 description 2
- 238000005534 hematocrit Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000001617 migratory effect Effects 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 150000002989 phenols Chemical class 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000012460 protein solution Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 241000269851 Sarda sarda Species 0.000 description 1
- 239000005708 Sodium hypochlorite Substances 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 235000015190 carrot juice Nutrition 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012847 fine chemical Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 235000015201 grapefruit juice Nutrition 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000002924 primary amino group Chemical class [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 235000013547 stew Nutrition 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 229940092665 tea leaf extract Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
- A61K38/063—Glutathione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
Definitions
- the present invention relates to a composition having anti-oxidative activity that is derived from natural extracts of animals and plants, and more particularly to an antioxidant composition that can exhibit anti-oxidative activity in the living body against active oxygen species which are produced in the body.
- the present invention provides a novel antioxidant composition that enables the preparation of food products and food product ingredients that provide protection against a wide range of lifestyle diseases, more specifically, protection against diabetes-related diseases in diabetic patients who have a markedly high level of active oxygen, by eliminating oxidative stress caused by active oxygen produced within the body.
- antioxidants are used to remove these types of active oxygen, but sufficient investigations have not been performed to determine whether these antioxidants are effective against all active oxygen species or only a limited number of species thereof.
- the inventors investigated the effects of antioxidants on the oxidative degradation of protein by various active oxygen species, and these investigations revealed that different antioxidants are effective against different active oxygen species, and there are very few antioxidants that are effective against all active oxygen species in the body.
- substances that have potent antioxidative action include the following: against the hypochlorite radical (ClO.), the peptides anserine and carnosine, reduced glutathione (GSH), and sulfur-containing amino acids or analogs thereof that are present in the bodies of various species of animals; against the peroxynitrite radical (ONOO.), vitamin C (L-ascorbic acid, V.C.); and against the hydroxyl radical (OH.), vitamin E ( ⁇ -tocopherol, V.E.).
- O. peroxynitrite radical
- OH. hydroxyl radical
- vitamin E ⁇ -tocopherol
- Possible causes include the following: first, there are many active oxygen species produced in the body, and it is almost impossible to eliminate all of their damaging effects with a single antioxidant; furthermore, with the exception of V.C., most of the other antioxidants derived from plants have a structural backbone such as a phenol group, etc., that exhibits the property of lipid solubility, and polyphenols are so poorly absorbed by the human gastrointestinal tract that the amount absorbed into the body is no more than 1/1000 of the amount ingested orally, etc. Therefore, most of these antioxidants have not sufficiently displayed efficacy in the body even when they have demonstrated extremely potent antioxidant activity in vitro.
- the peptides anserine and carnosine, reduced glutathione (GSH), and sulfur-containing amino acids obtained from animal materials have strong antioxidant activity against ClO.; V.C., which is a water-soluble vitamin, has strong antioxidant activity against ONOO.; and V.E., which is a fat-soluble vitamin, has strong antioxidant activity against OH..
- GSH reduced glutathione
- V.E. which is a fat-soluble vitamin
- antioxidants with potent OH.-scavenging activity have, similarly to V.E., the property of exhibiting almost no antioxidative activity against ClO. and ONOO. at physiologically relevant low concentrations, it is essential that they used in combination with the ClO.-scavenging anserine-carnosine mixture and the ONOO.-scavenger V.C., thus arriving at the present invention.
- the present invention consists of the following technical means.
- An antioxidant composition having the effect of suppressing three active oxygen species, i.e. hypochlorite radicals, hydroxyl radicals, and peroxynitrite radicals, with respect to active oxygen species produced in the body, the antioxidant composition comprising a mixture in which at least 20 mg of vitamin C (L-ascorbic acid or L-ascorbate) as an agent to scavenge peroxynitrite active oxygen, and at least 2 mg of caffeic acid analogue compound(s), at least 10 mg of polyphenyol compound(s) or at least 1.5 mg of carotenoid compound(s) as an agent to scavenge hydroxyl radical active oxygen are combined with 100 mg of histidine-containing dipeptide, or sulfur-containing amino acids or analogues thereof as an agent for scavenging hypochlorite active oxygen.
- active oxygen species i.e. hypochlorite radicals, hydroxyl radicals, and peroxynitrite radicals
- the antioxidant composition according to (1) above wherein the histidine-containing dipeptide of the agent for scavenging hypochlorite active oxygen is a mixture of anserine and carnosine, which are histidine-containing peptides contained in animal extract that is obtained by extraction with hot water from the muscles of poultry, cattle, pigs, and migratory fish, and the sulfur-containing amino acid or analogue thereof is one or more species of reduced glutathione, cysteine, acetylcysteine, methionine, and alliin obtained from extracts of plants of the Allium or Brassica families.
- the caffeic acid analogue is one extracted from plants of the wheat or poaceae families.
- the antioxidant composition according to (1) above wherein the polyphenol compound is the catechin extracted from mulberry leaves or tea leaves, and/or the quercetin extracted from the Allium family.
- the carotenoid compound is astaxanthin extracted from fish meat or algae, and/or the ⁇ -carotene extracted from plants selected from ashitaba ( Angelica keiskei ), pumpkin, carrot, mugwort, perilla, or kale.
- the antioxidant composition according to (1) above which has an effect of lowering concentration of water-soluble cholesterol in blood, wherein at least 20 mg of vitamin C (L-ascorbic acid or L-ascorbate) as an agent to scavenge peroxynitrite active oxygen, and at least 2 mg of caffeic acid analogue compound(s) as an agent to scavenge hydroxyl radical active oxygen are combined with 100 mg of the histidine-containing dipeptide, or sulfur-containing amino acids or analogues thereof as an agent for scavenging hypochlorite active oxygen.
- vitamin C L-ascorbic acid or L-ascorbate
- caffeic acid analogue compound(s) as an agent to scavenge hydroxyl radical active oxygen
- histidine-containing dipeptide, or sulfur-containing amino acids or analogues thereof as an agent for scavenging hypochlorite active oxygen is a mixture of anserine and carnosine, and the caffeic acid anclogue compound(s) a water soluble ferulic acid, chlorogenic acid, cinnamic acid, or caffeic acid.
- the antioxidant composition according to (1) above wherein at least 20 mg of vitamin C (L-ascorbic acid or L-ascorbate) as an agent to scavenge peroxynitrite active oxygen, and at least 2 mg of ubiquinone compound as an agent to scavenge hydroxyl radical active oxygen are combined with 100 mg of the histidine-containing dipeptide, or sulfur-containing amino acids or analogues thereof as an agent for scavenging hypochlorite active oxygen.
- the antioxidant food characterized by comprising the antioxidant composition defined in (1) above.
- the antioxidant food characterized by comprising the antioxidant composition defined in (6) above.
- antioxidants derived from animal extracts complements the deficiencies of antioxidants derived from plant extracts and vice versa; therefore, natural materials containing the aforementioned ClO.-scavenger, OH.-scavenger and ONOO.-scavenger were selected to constitute an antioxidant composition that can completely scavenge three active oxygen species produced in the body.
- the anserine-carnosine mixture having a potent ClO.-scavenging action is contained in abundance in the extracts of various meat, chicken, and the meat of large migratory fish such as tuna, bonito, salmon, etc.; sulfur-containing amino acids are contained in abundance in the extracts of Allium plants such as onions and Brassica plants such as cabbage. V.C.
- curcumin is contained in abundance in the extract of tumeric, and ferulic acid, etc., are contained in abundance in extracts obtained from wheat and rice, for example, wheat grass extract and rice bran extract, etc.
- OH.-scavenging capability of these extracts was tested, each demonstrated a potent antioxidant action toward OH. ( FIG. 2 ).
- the recommended daily amount for V.C. ranges from ⁇ 60 mg to ⁇ 5200 mg, and for V.E. from ⁇ 3 mg to ⁇ 5300 mg. Based on these amounts, when the dose or amount to be ingested of each type of ingredient was estimated from the results of tests conducted in the present invention, the following were obtained.
- anserine-carnosine, anserine-carnosine mixture or sulfur-containing amino acids which are agents that scavenge ClO., had sufficient antioxidant action to completely inhibit the proteolytic action of a 10 mM concentration of ClO..
- a 1 mM concentration of V.C. or sodium V.C. completely inhibited the oxidative effect of a 5 mM concentration of ONOO.
- a 0.5 ⁇ M concentration of carotenoids, 2.5 ⁇ M concentration of caffeic acid, or 2.5 ⁇ M concentration of polyphenols completely inhibited the oxidative action of a 10 mM concentration of OH..
- There is a problem with the gastrointestinal absorption of polyphenols and because among the active oxygen species produced in the body, OH. is produced in large quantities, the amount of polyphenols in the composition needs to be set higher.
- the concentration of active oxygen produced in the body changes depending on the physiological conditions, but it is estimated to reach maximum levels of several 10 ⁇ M to several 100 ⁇ M locally, and if we standardize the minimum blood concentration of each antioxidant when the antioxidant composition of the present invention is taken once a day, an amount equivalent to 500 ⁇ M of the ClO.-scavenger anserine-carnosine (a dose of approximately 600 mg calculated for a blood volume of 5000 mL), an amount equivalent to 200 ⁇ M of the ONOO.-scavenger V.C. (a dose of approximately 90 mg), and in consideration of the proportion of OH.
- OH.-scavengers amounts equivalent to 0.5 mM of carotenoids (a dose of approximately 1.5 mg), 2.5 ⁇ M of caffeic acid analogue (a dose of 5 to 10 mg), and 2.5 mM of polyphenols (a dose of 4 mg) should be sufficient to prevent the damaging effects of active oxygen.
- the calculated amounts in the composition are 20 mg or more of the ONOO.-scavenger V.C., and in consideration of the gastrointestinal absorption of the OH.-scavengers, 1.5 mg or more of carotenoids for a minimum blood concentration (M. Osterile, et al., Journal of Nutritional Bichemistry, No. 11, p.
- the antioxidants of the present invention wherein these OH.-scavengers are modified are ones that have antioxidant activity equivalent to a composition containing 20 mg of V.C. and 20 mg of V.E. per 100 mg of anserine-carnosine mixture, and it has been found that the formulation of combinations of a food ingredients with a an extremely wide range of selection branches from animal extracts to various plant extracts is possible, and the formulation of antioxidant foods that can prevent the harmful effects of active oxygen produced in the body becomes easier thereby.
- the each ingredient can be arranged in the form of the chemical compound itself or the material containing the compound derived from natural sources.
- the present invention is characterized in that the antioxidant agent, food or food material containing the antioxidant compound or material as the main ingredient which is constructed as the specific subject matter of the present invention has the effect of scavenging 3 types of the active oxygens of ClO. redical, OH. radical and NO 3 . radical simultaneously in the body, said radicals are produced in the body.
- Clo. was prepared using a method wherein sodium hypochlorite was diluted to a pH 6.5 with distilled water, OH. by a partially modified Fenton method (B. Halliwell, et al., Analytical Biochmistry, No. 165, p. 215-219, 1987), and NO 3 . by a modified quenching flow reactor method (R. Radi, et al., Journal of Biological Chemistry, Vol. 266, p. 4244-4250, 1991).
- Ova was dissolved in pH 7.2 buffered physiological saline to a concentration of 2.5 mg/mL, each concentration of antioxidant was added at a volume ratio of 10:1 with respect to the protein solution, the solution was let stand for 30 min at room temperature, each concentration of active oxygen was added in the same manner at a volume ratio of 10:1 with respect to protein solution, and ClO.oxidation was performed for 30 min at 37° C., OH. oxidation for 60 min at 37° C., and NO 3 oxidation for 120 min at 37° C.
- Degradation rate (%) (Peak area of protein degraded by active oxygen at the time the antioxidant was added/Peak area of undegraded control protein) ⁇ 100
- FIG. 1 shows the inhibitory action of each antioxidant toward Ova oxidative degradation by the three active oxygen species.
- the purified anserine-carnosine mixture from chicken extract completely inhibited oxidative degradation by ClO.; in addition, faint inhibitory activity was seen with by V.C., ⁇ -carotene and epigallocatechin gallate (EGCG).
- the concentrations of ⁇ -carotene and EGCG were 20 ⁇ M and 500 ⁇ M, respectively, but these are concentrations equivalent to no less than 100 times concentrations that are physiologically relevant, so they were impractical.
- FIG. 2 shows the results of SDS-PAGE.
- chicken extract contains anserine and carnosine
- salmon extract contains anserine
- cabbage extract contains sulfur-containing amino acids and V.C.
- Salmon extract, carrot extract, green tea extract, tumeric extract, and cabbage extract exhibited strong inhibitory effects on oxidative degradation by OH., and this was followed in order by inhibitory effects exhibited by wheat grass extract, rice bran extract, onion extract and mulberry leaf extract. The inhibitory effects of chicken extract and lemon juice were extremely weak.
- Salmon extract contains not only anserine, but also astaxanthin, carrot juice contains ⁇ -carotene, green tea extract contains EGCG, tumeric extract contains curcumin, and cabbage extract contains not only sulfur-containing amino acids and V.C., but also catechins and caffeic acid analogues.
- Wheat grass extract and rice bran extract contain caffeic acid analogues such as ferulic acid, etc.
- onion extract contains quercetin
- mulberry leaf extract contains catechins and caffeic acid analogues.
- Lemon extract exhibited the most potent inhibitory effect on oxidative degradation by ONOO., and inhibitory effects on oxidative degradation were also seen with salmon extract, onion extract, cabbage extract, and chicken extract.
- lemon juice and cabbage contain V.C.
- Onions and mulberry leaves contain not only V.C. but also reduced glutathione and catechins
- chicken extract and salmon extract contain not only anserine and carnosine, but also various amino acids.
- Table 2 shows a summary of these antioxidant effects.
- Table 3 shows a comparison of the concentrations of various antioxidants with ClO.-scavenging action that completely inhibit the oxidative degradation of proteins shown by a concentration of 10 mM of ClO.; reduced glutathione, L-cysteine, and N-acetyl-L-cysteine were the most potent, followed in order by anserine and carnosine dipeptides, methionine, cysteic acid and alliin.
- Table 4 shows the results of the comparison of the concentrations of various antioxidants that will completely inhibit the proteolytic action of a 10 mM concentration of OH. that was performed in the same manner for antioxidants with an antioxidant action on OH..
- the strongest antioxidant effect against oxidative degradation of protein by OH. was shown by the carotenoids astaxanthin and ⁇ -carotene, the polyphenols quercetin and catechins, and the caffeic acid analogues curcumin, ferulic acid, chlorogenic acid, and caffeic acid in that order, and among the items tested V.E. had the weakest antioxidant activity.
- FIG. 4 shows one example, and in this test an anserine-carnosine mixture (2.5 mM) from chicken extract as the ClO.-scavenger, EGCG (50 ⁇ M) as the OH.-scavenger, and V.C. (2.5 mM) as the ONOO.-scavenger were used. These three types were mixed together and used as the antioxidant mixture. As shown in FIG. 4 , the red blood cell transit damage due to each species of antioxidant was completely inhibited by the respective antioxidants, and the antioxidant mixture was effective in completely inhibiting the damage caused by each active oxygen species.
- ClO.-scavenger 200 mg/kg of anserine-carnosine mixture derived from chicken extract as the OH.-scavenger wheat grass extract (total content of caffeic acid analogues 10 mg/kg), as the ONOO.-scavenger 100 mg/kg of V.C., and a composition containing all three antioxidants were administered orally to the GK rats for 28 days, and the blood HbAlc levels were measured at the end of dosing.
- OH.-scavenger wheat grass extract total content of caffeic acid analogues 10 mg/kg
- ONOO.-scavenger 100 mg/kg of V.C. a composition containing all three antioxidants were administered orally to the GK rats for 28 days, and the blood HbAlc levels were measured at the end of dosing.
- chlorogenic acid and ferulic acid which are caffeic acid analogue compounds used in the present invention also have an effect of lowering the level of cholesterol in the blood as an agent for scavenging OH. Radical (A. Herrera-Arellano et al., Phytomedicine, Vol. 11, p. 561-566, 2004; H. K. Kim et al., Clinica Chimica Acta, Vol. 327, p. 129-137, 2003).
- the results obtained is shown in FIG. 4-FIG . 6 .
- the value of the concentration of the total cholesterol in the blood of 12 members before the administration the value was higher than 200 mg/dL before the administration, and the mean total cholesterol in the blood was lowered from 233.8 ⁇ 19.9 mg/dL to 219.3 ⁇ 24.2 mg/dL (p ⁇ 0.05) after the administration.
- the value of LDL cholesterol of other 12 members before and after the administration the value was higher than 120 mg/dL before the administration, and the mean LDL value in the blood was lowered from 149.0 ⁇ 16 mg/dL to 135.0 ⁇ 16.4 mg/dL (p ⁇ 0.05) after the administration.
- the value of cholesterol in the blood of 8 patients with high cholesterol value in the blood was higher than 220 mg/dL before the administration, and the value thereof was lowered from 124.9 ⁇ 57.1 mg/dL to 91.6 ⁇ 29.4 mg/dL (p ⁇ 0.05) after the administration.
- each antioxidant toward Ova oxidative degradation by the three active oxygen species and agent arranged with three ingredients containing CoQ10 is shown in FIG. 9 .
- a microchannel which is a capillary model, is a device that measures hemorheology, i.e., the capability of blood to circulate through capillaries. Factors effecting hemorheology include meals, oxidative stress, etc.
- MC microchannel
- FIG. 1 shows the inhibitory effect of various antioxidants on ovalbumin degradation by active oxygen.
- A represents oxygen degradation by 10 mM of the ClO radical
- B represents oxygen degradation by 10 mM of the OH radical
- C represents oxygen degradation by the ONOO radical.
- the symbols used in each panel for the added sample materials are as follows: R is untreated ovalbumin, C is oxidatively degraded control ovalbumin, 1 is the purified anserine-carnosine mixture, 2 is vitamin C, 3 is vitamin E, 4 is astaxanthin, 5 is ⁇ -carotene, 6 is catechin, 7 is quercetin, 8 is epigallocatechin gallate (EGCG), 9 is curcumin, 10 is chlorogenic acid, and 11 is ferulic acid (the concentrations are shown in Table 1);
- FIG. 2 shows the inhibitory effect of various natural ingredients on the degradation of ovalbumin by active oxygen.
- A represents oxidative degradation by 10 mM of the ClO radical
- B represents oxidative degradation by 10 mM of the OH radical
- C represents oxidative degradation by the ONOO radical.
- R is untreated ovalbumin
- C is oxidatively degraded control ovalbumin
- 1 is chicken extract
- 2 is lemon juice
- 3 rice bran extract
- 4 salmon extract
- 5 carrot extract
- 6 is mulberry leaf extract
- 7 is onion extract
- 8 tea leaf extract
- 9 is tumeric extract
- 10 is cabbage extract
- 11 is wheat grass extract (the concentrations are shown in Table 2);
- FIG. 3 shows the microchannel transit capability of human blood constituents.
- A is blood treated with ClO radical
- B is blood treated with OH radical
- C is blood treated with ONOO radical.
- the bars in the graph from left to right represent plasma, white blood cells, and red blood cells;
- FIG. 4 shows the effect of each active oxygen species on human red blood cells and the effect of each species of antioxidant on microchannel transit capability.
- A is blood treated with ClO radical
- B is blood treated with OH radical
- C is blood treated with ONOO radical.
- the bars in the graph from left to right represent control, addition of ClO.-scavenger, addition of OH.-scavenger, addition of ONOO.-scavenger, and the mixture of three species of antioxidants;
- FIG. 5 shows the effect of various species of antioxidants in decreasing the blood HbAlc concentration in diabetes model GK rats
- FIG. 6 shows concentration of the total cholesterol in each blood samples of 12 members of healthy volunteers
- FIG. 7 shows concentration of LDL cholesterol in each blood samples of 12 members of healthy volunteers
- FIG. 8 shows concentration of the neutral fat in blood samples of 8 members with high cholesterol value
- FIG. 9 shows the inhibition effect on the degradation of ovoalbumin due to active oxygen species by each antioxidant.
- A is the oxidative degradation by 10 mM of ClO radical
- B is that by 10 mM of OH radical
- C is that by ONOO radical.
- R is untreated ovoalbumin
- C is oxidatively degradated ovoalbumin as blank
- 1 is 5 mM of anserine-carnosine mixture from chicken extract
- 2 is 5 mM of vitamin C
- 3 is 50 ⁇ M of CoQ10
- 4 is antioxidant arranged with the above three ingredients;
- FIG. 10 shows effectiveness of antioxidants in preventing damage by active oxygen on the microchannel transit capability of human red blood cells.
- Pannel A is the oxidative degradation by 10 mM of 010 radical
- panel B is that by 10 mM of Oh radical
- panel C is that by 5 mM of ONOO radical.
- Each panel shows, from left to right, a blank without any antioxidants, added with anserine-carnosine from chicken extract, added with vitamin C, added with CoQ10, and added with these 3 ingredients respectively; and
- FIG. 11 shows effect on the improvement of the liquidity of blood of healthy volunteers.
- a 20% solid concentrate was prepared by vacuum concentration of 40 L of chicken extract obtained by hot water extraction from 10 kg of whole chicken carcasses.
- the content of anserine-carnosine mixture in this concentrated chicken extract was 140 mg/g per solid substance.
- To 1200 g of the concentrated chicken extract were added 16.8 g of V.C. (food additive) and 840 g of concentrated wheat grass extract prepared by obtaining an extract by hot water extraction from wheat grass and concentrating it to contain 10% solids and a 0.2% caffeic acid analogues; 60 g of non-digestible dextrin was added and mixed; and spray drying was performed to obtain approximately 400 g of antioxidant composition powder containing an ClO.-scavenger, OH.-scavenger, and ONOO.-scavenger.
- the final content was 84 mg of anserine-carnosine, 42 mg of V.C., and 4 mg of caffeic acid analogues per 1 g of powder. It was confirmed that this powder exhibits a blood HbAlc level lowering effect in tests using the aforementioned diabetes model rats.
- red salmon paste To 5 kg of gutted and boned salmon was added 15 kg of water, and the mixture was boiled for 3 hr at 100° C., and then homogenized in a mixer; a 0.2% concentration of proteolytic enzyme was added, and hydrolysis was performed for 4 hr at 45° C. to prepare a red salmon paste.
- To 20 kg of the red salmon paste was added 1 kg of the concentrated whole chicken extract from Example 1, 60 g of sodium V.C., 10 g of green tea extract powder (catechin content 20%), 40 g of seasoning liquid, and 100 g of dextrin; and spray drying was performed to prepare approximately 2 kg of salmon extract containing the antioxidant mixture.
- the content was 50 mg of anserine-carnosine, 25 mg of V.C., 1 mg of astaxanthin as total carotenoid, and 10 mg of catechins per 1 g of powder.
- a 1% solution of this powder completely inhibited the proteolytic action of the three active oxygen species.
- Chicken extract was filtered through a 3,000 molecular weight fraction ultrafiltration membrane (SEP-3013, Asahi Kasei Corporation), and the filtrate that passed through the ultrafiltration membrane was concentrated to purify the anserine-carnosine mixture using a chromatograph packed with Dowex 50Wx8 cationic exchange resin.
- rice bran extract obtained from the hot water extraction of rice bran was added to activated carbon, and decolorization, filtering, and concentration to a solid content of 20% were performed to prepare a concentrated rice bran extract containing caffeic acid analogues.
- grapefruit were placed in a mixer and after mixing, the fruit juice obtained thereby was filtered to remove insolubles.
- the chicken extract obtained by boiling-water extraction of hole chicken was concentrated, freeze-dried to produce chicken extract powder containing 10% of anserine-carnosine.
- To 2.0 g of the chicken extract powder 150 mg of V.C. (food additive), 200 mg (10 mg as CoQ10) of CoQ10 (made by Nisshin pharma), further, 80 g of corn powder, 1 g of onion powder and 1 g of seasoning were added to produce instant corn soup powder.
- This corn soup powder 12.6 g was dissolved into 100 mL of 80° C. hot water to obtain corn potage soup enriched with the antioxidant composition.
- the present invention relates to an antioxidant composition, and antioxidant compositions that act effectively against a wide range of active oxygen species can be provided thereby.
- foods containing a single antioxidant have been widely used to prevent aging and prevent lifestyle related diseases.
- various diseases wherein arteriosclerosis and hypertension, cancer, diabetes and various diseases accompanied with diabetes.
- satisfactory results have not always been obtained.
- the clinical effectiveness obtained in vitro and by forced administration to animals may not be realized in humans due to problems with gastrointestinal absorption and distribution throughout the body when taken orally.
- the active oxygen in the body that causes aging and lifestyle diseases is not a single entity and various species are produced depending on the physiological conditions and lifestyles of human beings.
- the strength of antioxidant activity has been evaluated using active oxygen that has only meager correlation with the active oxygen produced in the body, and the ranking of intensity has been stipulated using those criteria.
- the actions of various species of antioxidant at physiologically relevant concentrations are specific with respect to each active oxygen species, and it has become clear that substances that have been evaluated in the past as having weak antioxidant activity demonstrate powerful antioxidant activity against a specific active oxygen species, and conversely, substances that have been evaluated as having strong antioxidant activity actually have only weak activity against some active oxygen species. Based on these findings, with foods having a single antioxidant as the main ingredient it has been impossible to satisfactorily prevent various diseases that emerge due to various active oxygen species produced in the body.
- the active oxygen species produced in the body are divided into three groups, and antioxidants for the active oxygen species of the OH. system produced from oxygen gas, and of the chlorine system and nitric oxide system produced by white blood cells are identified.
- the present invention has revealed that peptides and sulfur-containing amino acids that constitute peptides have a strong antioxidant action against the active oxygen of the chlorine system, carotenoids and polyphenols from plans and substances that have a hydrophobic group such as phenols have a strong antioxidant action against the active oxygen of the OH. system, and vitamin C, etc., have a strong antioxidant action against the active oxygen of the nitric oxide system.
- antioxidant composition act effectively against a wide range of active oxygen species, and in fact, because it has been recognized that the combined use of antioxidants markedly inhibits the production of ultimately glycated products in the body that occur due to oxidative damage, it is possible to provide antioxidant foods that are even more effective in preventing the emergence of aging and lifestyle disease than in the past. In addition, it is possible to manufacture antioxidant food ingredients that are even more effective by combining natural ingredients that contain these antioxidant constituents.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
An object of the present invention is to provide an antioxidant composition that is effective in the living body against active oxygen species produced in the body. The present invention provides an antioxidant composition having the effect of suppressing three active oxygen species, i.e. hypochlorite radicals, hydroxyl radicals, and peroxynitrite radicals, with respect to active oxygen species produced in the body, the antioxidant composition comprising a mixture in which at least 20 mg of vitamin C (L-ascorbic acid or sodium L-ascorbate) as an agent to scavenge peroxynitrite active oxygen, and at least 2 mg of caffeic acid analogue compound(s), at least 10 mg of polyphenyol compound(s) or at least 1.5 mg of carotenoid compound(s) as an agent to scavenge hydroxyl radical active oxygen are combined with 100 mg of histidine-containing dipeptide, or sulfur-containing amino acids or analogues thereof obtained from animal extract as an agent for scavenging hypochlorite active oxygen.
Description
- 1. Field of the Invention
- The present invention relates to a composition having anti-oxidative activity that is derived from natural extracts of animals and plants, and more particularly to an antioxidant composition that can exhibit anti-oxidative activity in the living body against active oxygen species which are produced in the body. The present invention provides a novel antioxidant composition that enables the preparation of food products and food product ingredients that provide protection against a wide range of lifestyle diseases, more specifically, protection against diabetes-related diseases in diabetic patients who have a markedly high level of active oxygen, by eliminating oxidative stress caused by active oxygen produced within the body.
- 2. Description of Related Art
- In recent years in Japan the increasing number of various geriatric diseases associated with an aging population and the increased human and economic burden of medical care thereof have become extremely serious problems. The aging of organisms and the onset of disease are, in a sense, inextricably related, and therefore it is unavoidable that as the population ages, the number of people with diseases will also increase. Thus, it is important to delay the progression of aging in humans as much as possible to suppress the onset of disease.
- The primary cause of aging in human beings is the fact that the cells constituting the body are limited in the number of times they can divide and propagate to regenerate tissue, and the number of cellular divisions reaches its limit and tissue regeneration capability decreases because cells are subjected to various kinds of damage. Aging progresses due to factors that damage cells, for example, exposure to ultraviolet light and radiation, chemicals, etc., and to active oxygen that is produced within the bodies of living organisms. More specifically, active oxygen is a substance that is naturally produced by organisms that utilize oxygen to perform energy metabolism, and in that sense, it can be said that the aging we undergo occurs naturally. Therefore, the suppression of the harmful effects of active oxygen that is produced within the body plays an important role as a primary countermeasure to delay aging and suppress the onset of age-related diseases.
- In the past various antioxidants have appeared on the market, but almost all were prepared from a single constituent or single starting material. However, there are many different active oxygen species produced in the body, and concrete examples include superoxide (O2 −) produced from oxygen gas incorporated into the body. This O2 − is converted to hydrogen peroxide (H2O2) by an enzyme called superoxide dismutase (SOD), and the H2O2 goes on to generate a hydroxyl radical (OH.) by transition metal catalysis. In addition to H2O2, white blood cells produce active oxygen to destroy bacteria that invade the body, and these forms of active oxygen include the hypochlorite radical, nitric oxide radical, etc.
- On the one hand, various species of antioxidants are used to remove these types of active oxygen, but sufficient investigations have not been performed to determine whether these antioxidants are effective against all active oxygen species or only a limited number of species thereof. The inventors investigated the effects of antioxidants on the oxidative degradation of protein by various active oxygen species, and these investigations revealed that different antioxidants are effective against different active oxygen species, and there are very few antioxidants that are effective against all active oxygen species in the body. In other words, substances that have potent antioxidative action include the following: against the hypochlorite radical (ClO.), the peptides anserine and carnosine, reduced glutathione (GSH), and sulfur-containing amino acids or analogs thereof that are present in the bodies of various species of animals; against the peroxynitrite radical (ONOO.), vitamin C (L-ascorbic acid, V.C.); and against the hydroxyl radical (OH.), vitamin E (α-tocopherol, V.E.). It has already been confirmed that combinations and compositions of antioxidants wherein antioxidants are used together rather than independently are effective in completely eliminating the damage caused by active oxygen produced in the body (see Japanese Patent Application No. 2003-025210).
- In the past various antioxidants have been tested for the prevention of various types of diseases, and lifestyle diseases in particular. For example, these include polyphenols such as V.C., V.E., β-carotene, catechins, etc. However, when we look at the prevention of diseases, e.g., the prevention of diseases such as cancer, etc., by these antioxidants, few findings show that they are effective. Conversely, most results show that they have no clinical efficacy (see J. Kaikkonen, et al. Free Radicals Research, Vol. 33, p. 329-340, 2000), and antioxidants have not provided the effect of preventing diseases and aging as much as had been expected. Possible causes include the following: first, there are many active oxygen species produced in the body, and it is almost impossible to eliminate all of their damaging effects with a single antioxidant; furthermore, with the exception of V.C., most of the other antioxidants derived from plants have a structural backbone such as a phenol group, etc., that exhibits the property of lipid solubility, and polyphenols are so poorly absorbed by the human gastrointestinal tract that the amount absorbed into the body is no more than 1/1000 of the amount ingested orally, etc. Therefore, most of these antioxidants have not sufficiently displayed efficacy in the body even when they have demonstrated extremely potent antioxidant activity in vitro.
- To overcome these deficiencies, it is important to have an antioxidant composition that can counteract the wide range of active oxygen species and to select materials that can sufficiently counteract the OH. produced in the process of energy metabolism. As noted above, the peptides anserine and carnosine, reduced glutathione (GSH), and sulfur-containing amino acids obtained from animal materials have strong antioxidant activity against ClO.; V.C., which is a water-soluble vitamin, has strong antioxidant activity against ONOO.; and V.E., which is a fat-soluble vitamin, has strong antioxidant activity against OH.. However, the strong antioxidant activity of V.E. against OH. is one that inhibits proteolysis, and when we compare it with other antioxidants derived from plants, this activity is approximately 1/5000 that of the carotenoid astaxanthin, 1/2000 to 1/1000 that of the polyphenol catechins and quercetin, and 1/1000 to 1/500 that of caffeic acid derivatives (Table 1). Therefore, even though V.E. is absorbed well by the gastrointestinal tract and it is distributed throughout the whole body, a large amount must be ingested to scavenge OH.. However, there are problems with V.E. because the maximum daily dose to be taken by adults is 300 mg, it is harmful if taken in excess, and because it is an oil, it suffers a loss of antioxidant activity during storage and food processing becomes difficult.
- After reviewing the above prior art and reflecting on the status quo, the inventors conducted diligent research with the goal of developing a novel antioxidant composition that will enable solution of the aforementioned problems, and upon searching for antioxidant ingredients having strong OH.-scavenging capability to replace or potentiate V.E., they discovered that, as noted above, polyphenols such as catechins and quercetin, phenol compounds such as the caffeic acid analogues curcumin and ferulic acid, and the carotenoids astaxanthin and β-carotene have potent antioxidative action against OH. (
FIG. 1 ). The inventors also discovered that because these antioxidants with potent OH.-scavenging activity have, similarly to V.E., the property of exhibiting almost no antioxidative activity against ClO. and ONOO. at physiologically relevant low concentrations, it is essential that they used in combination with the ClO.-scavenging anserine-carnosine mixture and the ONOO.-scavenger V.C., thus arriving at the present invention. - An object of the present invention is to provide an antioxidant composition that exhibits antioxidative capability in the body against a variety of active oxygen species produced in the body.
- To solve the above problems, the present invention consists of the following technical means.
- (1) An antioxidant composition having the effect of suppressing three active oxygen species, i.e. hypochlorite radicals, hydroxyl radicals, and peroxynitrite radicals, with respect to active oxygen species produced in the body, the antioxidant composition comprising a mixture in which at least 20 mg of vitamin C (L-ascorbic acid or L-ascorbate) as an agent to scavenge peroxynitrite active oxygen, and at least 2 mg of caffeic acid analogue compound(s), at least 10 mg of polyphenyol compound(s) or at least 1.5 mg of carotenoid compound(s) as an agent to scavenge hydroxyl radical active oxygen are combined with 100 mg of histidine-containing dipeptide, or sulfur-containing amino acids or analogues thereof as an agent for scavenging hypochlorite active oxygen.
(2) The antioxidant composition according to (1) above, wherein the histidine-containing dipeptide of the agent for scavenging hypochlorite active oxygen is a mixture of anserine and carnosine, which are histidine-containing peptides contained in animal extract that is obtained by extraction with hot water from the muscles of poultry, cattle, pigs, and migratory fish, and the sulfur-containing amino acid or analogue thereof is one or more species of reduced glutathione, cysteine, acetylcysteine, methionine, and alliin obtained from extracts of plants of the Allium or Brassica families.
(3) The antioxidant composition according to (1) above, wherein the caffeic acid analogue is one extracted from plants of the wheat or poaceae families.
(4) The antioxidant composition according to (1) above, wherein the polyphenol compound is the catechin extracted from mulberry leaves or tea leaves, and/or the quercetin extracted from the Allium family.
(5) The antioxidant composition according to (1) above, wherein the carotenoid compound is astaxanthin extracted from fish meat or algae, and/or the β-carotene extracted from plants selected from ashitaba (Angelica keiskei), pumpkin, carrot, mugwort, perilla, or kale.
(6) The antioxidant composition according to (1) above which has an effect of lowering concentration of water-soluble cholesterol in blood, wherein at least 20 mg of vitamin C (L-ascorbic acid or L-ascorbate) as an agent to scavenge peroxynitrite active oxygen, and at least 2 mg of caffeic acid analogue compound(s) as an agent to scavenge hydroxyl radical active oxygen are combined with 100 mg of the histidine-containing dipeptide, or sulfur-containing amino acids or analogues thereof as an agent for scavenging hypochlorite active oxygen.
(7) The antioxidant composition according to (1) above, wherein histidine-containing dipeptide, or sulfur-containing amino acids or analogues thereof as an agent for scavenging hypochlorite active oxygen is a mixture of anserine and carnosine, and the caffeic acid anclogue compound(s) a water soluble ferulic acid, chlorogenic acid, cinnamic acid, or caffeic acid.
(8) The antioxidant composition according to (1) above, wherein at least 20 mg of vitamin C (L-ascorbic acid or L-ascorbate) as an agent to scavenge peroxynitrite active oxygen, and at least 2 mg of ubiquinone compound as an agent to scavenge hydroxyl radical active oxygen are combined with 100 mg of the histidine-containing dipeptide, or sulfur-containing amino acids or analogues thereof as an agent for scavenging hypochlorite active oxygen.
(9) The antioxidant food characterized by comprising the antioxidant composition defined in (1) above.
(10) The antioxidant food characterized by comprising the antioxidant composition defined in (6) above.
(11) The antioxidant food characterized by comprising the antioxidant composition defined in (8) above. - Next, the present invention will be further described in detail.
- The effective use of antioxidants derived from animal extracts complements the deficiencies of antioxidants derived from plant extracts and vice versa; therefore, natural materials containing the aforementioned ClO.-scavenger, OH.-scavenger and ONOO.-scavenger were selected to constitute an antioxidant composition that can completely scavenge three active oxygen species produced in the body. The anserine-carnosine mixture having a potent ClO.-scavenging action is contained in abundance in the extracts of various meat, chicken, and the meat of large migratory fish such as tuna, bonito, salmon, etc.; sulfur-containing amino acids are contained in abundance in the extracts of Allium plants such as onions and Brassica plants such as cabbage. V.C. having a potent ONOO.-scavenging action is contained in large amounts in citrus fruits and in the extracts of Brassica plants such as cabbage, etc. On the other hand, with respect to the carotenoids such as astaxanthin and β-carotene having potent OH.-scavenging action, the former is contained in abundance in the extract of salmon, which is an animal, and extracts of algae, whereas the latter is contained in abundance in the extracts of green and yellow vegetables such as carrots, etc.; polyphenols such as catechins, epigallocatechin gallate, quercetin, etc., are contained in the respective extracts of plants such as mulberry leaves, green tea, onions, etc. In addition, among the caffeic acid analogues having a potent OH.-scavenging action, curcumin is contained in abundance in the extract of tumeric, and ferulic acid, etc., are contained in abundance in extracts obtained from wheat and rice, for example, wheat grass extract and rice bran extract, etc. In practice, when the OH.-scavenging capability of these extracts was tested, each demonstrated a potent antioxidant action toward OH. (
FIG. 2 ). - With respect to the doses or amounts of these antioxidants to be ingested by humans, there are no established doses; for example, the recommended daily amount for V.C. ranges from ≧60 mg to ≦5200 mg, and for V.E. from ≧3 mg to ≦5300 mg. Based on these amounts, when the dose or amount to be ingested of each type of ingredient was estimated from the results of tests conducted in the present invention, the following were obtained.
- At a concentration of 5 mM, anserine-carnosine, anserine-carnosine mixture or sulfur-containing amino acids, which are agents that scavenge ClO., had sufficient antioxidant action to completely inhibit the proteolytic action of a 10 mM concentration of ClO.. On the other hand, a 1 mM concentration of V.C. or sodium V.C. completely inhibited the oxidative effect of a 5 mM concentration of ONOO.. Furthermore, a 0.5 μM concentration of carotenoids, 2.5 μM concentration of caffeic acid, or 2.5 μM concentration of polyphenols completely inhibited the oxidative action of a 10 mM concentration of OH.. There is a problem with the gastrointestinal absorption of polyphenols, and because among the active oxygen species produced in the body, OH. is produced in large quantities, the amount of polyphenols in the composition needs to be set higher.
- The concentration of active oxygen produced in the body changes depending on the physiological conditions, but it is estimated to reach maximum levels of several 10 μM to several 100 μM locally, and if we standardize the minimum blood concentration of each antioxidant when the antioxidant composition of the present invention is taken once a day, an amount equivalent to 500 μM of the ClO.-scavenger anserine-carnosine (a dose of approximately 600 mg calculated for a blood volume of 5000 mL), an amount equivalent to 200 μM of the ONOO.-scavenger V.C. (a dose of approximately 90 mg), and in consideration of the proportion of OH. produced in the body, for the OH.-scavengers, amounts equivalent to 0.5 mM of carotenoids (a dose of approximately 1.5 mg), 2.5 μM of caffeic acid analogue (a dose of 5 to 10 mg), and 2.5 mM of polyphenols (a dose of 4 mg) should be sufficient to prevent the damaging effects of active oxygen. If the amount of each ingredient is expressed per 100 mg of the ClO.-scavenger anserine-carnosine mixture or sulfur-containing amino acids such as reduced glutathione, etc., the calculated amounts in the composition are 20 mg or more of the ONOO.-scavenger V.C., and in consideration of the gastrointestinal absorption of the OH.-scavengers, 1.5 mg or more of carotenoids for a minimum blood concentration (M. Osterile, et al., Journal of Nutritional Bichemistry, No. 11, p. 482-490, 2000), 2 mg or more of caffeic acid analogues, which encounter no particular problem with gastrointestinal absorption, and 1 mg or more of polyphenols such as catechins; however, in consideration of gastrointestinal absorption, a 10-fold greater amount of 10 mg or more is preferred (F. Catterall et al., Xenobiotica, No. 33, p. 743-753, 2003).
- The antioxidants of the present invention wherein these OH.-scavengers are modified are ones that have antioxidant activity equivalent to a composition containing 20 mg of V.C. and 20 mg of V.E. per 100 mg of anserine-carnosine mixture, and it has been found that the formulation of combinations of a food ingredients with a an extremely wide range of selection branches from animal extracts to various plant extracts is possible, and the formulation of antioxidant foods that can prevent the harmful effects of active oxygen produced in the body becomes easier thereby.
- In the present invention, the each ingredient can be arranged in the form of the chemical compound itself or the material containing the compound derived from natural sources. The present invention is characterized in that the antioxidant agent, food or food material containing the antioxidant compound or material as the main ingredient which is constructed as the specific subject matter of the present invention has the effect of scavenging 3 types of the active oxygens of ClO. redical, OH. radical and NO3. radical simultaneously in the body, said radicals are produced in the body. The above specific subject matter and the effect thereof are not obvious from the general knowledge in the field of the art to which the present invention is belonged.
- Next, the test examples of the present invention are described even more concretely.
- ClO., OH., and NO3. were prepared as three typical active oxygen species produced in the body. Clo. was prepared using a method wherein sodium hypochlorite was diluted to a pH 6.5 with distilled water, OH. by a partially modified Fenton method (B. Halliwell, et al., Analytical Biochmistry, No. 165, p. 215-219, 1987), and NO3. by a modified quenching flow reactor method (R. Radi, et al., Journal of Biological Chemistry, Vol. 266, p. 4244-4250, 1991). Next, Ova was dissolved in pH 7.2 buffered physiological saline to a concentration of 2.5 mg/mL, each concentration of antioxidant was added at a volume ratio of 10:1 with respect to the protein solution, the solution was let stand for 30 min at room temperature, each concentration of active oxygen was added in the same manner at a volume ratio of 10:1 with respect to protein solution, and ClO.oxidation was performed for 30 min at 37° C., OH. oxidation for 60 min at 37° C., and NO3 oxidation for 120 min at 37° C. After the reaction, sodium dodecylsulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was performed on each sample, the gel was stained with Coomassie blue R250, and the Ova degradation inhibition rate was calculated from the densitometer reading. An accurate degradation inhibition rate was calculated using the following formula from the proteolytic inhibition activity obtained by performing GPC-HPLC using a TSKG-3,000SW column directly on the reacted samples.
-
Degradation rate (%)=(Peak area of protein degraded by active oxygen at the time the antioxidant was added/Peak area of undegraded control protein)×100 -
FIG. 1 shows the inhibitory action of each antioxidant toward Ova oxidative degradation by the three active oxygen species. With respect to ClO., the purified anserine-carnosine mixture from chicken extract completely inhibited oxidative degradation by ClO.; in addition, faint inhibitory activity was seen with by V.C., β-carotene and epigallocatechin gallate (EGCG). The concentrations of β-carotene and EGCG were 20 μM and 500 μM, respectively, but these are concentrations equivalent to no less than 100 times concentrations that are physiologically relevant, so they were impractical. With respect to OH., 10 μM of astaxanthin and β-carotene, and 5 μM of catechins, quercetin, ECGC, and the caffeic acid analogues curcumin, chlorogenic acid, and ferulic acid completely inhibited the oxidative degradation of Ova, at the same level as V.E. with a concentration of 5 mM did. With respect to ONOO., 1 mM of V.C. completely inhibited the oxidative degradation, and in addition, β-carotene, catechins, and EGCG showed degradation inhibitory activity at respective concentrations of 10 μM, 500 μM and 500 μM, but those concentrations exceed physiologically relevant concentrations. Table 1 summarizes the degradation inhibitory activity. -
TABLE 1 Inhibitory Action of Antioxidants toward Proteolysis by Various Active oxygen species (%) ClO OH ONOO Antioxidant radical radical radical Anserine-carnosine (5 mM) 100 0 14 Vitamin C (5 mM) 67 0 100 Vitamin E (5 mM) 0 98 22 Astaxanthin (20 μM) 24 100 28 B-carotene (20 μM) 38 100 74 Catechins (50 μM) 0 100 58 Quercetin (50 μM) 5 100 16 Curcumin (500 μM) 16 100 13 Chlorogenic acid (50 μM) 0 100 28 Ferulic acid (50 μM) 7 100 34 - Using the same test methods as described in (1) above, a comparison of inhibitory activity by various natural extracts on the Ova degradation by active oxygen was performed. The concentrations of the natural extracts tested were 5 mg/mL as solids.
FIG. 2 shows the results of SDS-PAGE. - There were three types of natural extracts showing inhibitory effects on oxidative degradation by ClO.: chicken extract, salmon extract, and cabbage extract. Chicken extract contains anserine and carnosine, salmon extract contains anserine, and cabbage extract contains sulfur-containing amino acids and V.C. Salmon extract, carrot extract, green tea extract, tumeric extract, and cabbage extract exhibited strong inhibitory effects on oxidative degradation by OH., and this was followed in order by inhibitory effects exhibited by wheat grass extract, rice bran extract, onion extract and mulberry leaf extract. The inhibitory effects of chicken extract and lemon juice were extremely weak. Salmon extract contains not only anserine, but also astaxanthin, carrot juice contains β-carotene, green tea extract contains EGCG, tumeric extract contains curcumin, and cabbage extract contains not only sulfur-containing amino acids and V.C., but also catechins and caffeic acid analogues. Wheat grass extract and rice bran extract contain caffeic acid analogues such as ferulic acid, etc., onion extract contains quercetin, and mulberry leaf extract contains catechins and caffeic acid analogues. Lemon extract exhibited the most potent inhibitory effect on oxidative degradation by ONOO., and inhibitory effects on oxidative degradation were also seen with salmon extract, onion extract, cabbage extract, and chicken extract. With respect to the main ingredients of these extracts, lemon juice and cabbage contain V.C., Onions and mulberry leaves contain not only V.C. but also reduced glutathione and catechins, and chicken extract and salmon extract contain not only anserine and carnosine, but also various amino acids. Table 2 shows a summary of these antioxidant effects.
-
TABLE 2 Effects of Various Natural Extracts on Proteolysis by Each Active Oxygen Species Natural extract (solids OH ONOO 0.5%) ClO radical radical radical Chicken extract 100 28 82 Lemon juice 52 12 100 Rice bran extract 0 100 12 Salmon extract 100 100 100 Carrot extract 4 100 28 Mulberry leaf extract 12 76 52 Onion extract 38 92 88 Green tea extract 0 100 40 Tumeric extract 0 100 0 Cabbage extract 89 100 73 Wheat grass extract 16 98 52 - The strength of antioxidant activity between peptides with antioxidant activity and sulfur-containing amino acids was compared with respect to ClO., and between various antioxidants with antioxidant activity with respect to OH.. Table 3 shows a comparison of the concentrations of various antioxidants with ClO.-scavenging action that completely inhibit the oxidative degradation of proteins shown by a concentration of 10 mM of ClO.; reduced glutathione, L-cysteine, and N-acetyl-L-cysteine were the most potent, followed in order by anserine and carnosine dipeptides, methionine, cysteic acid and alliin.
-
TABLE 3 Strength of ClO•-Scavenging Action ClO radical inhibitory Antioxidant concentration (mM) Anserine 5.0 Carnosine 5.0 Anserine-carnosine mixture 5.0 Reduced glutathione 2.5 Cysteine 2.5 N-acetyl-L-cysteine 2.5 Cysteic acid 7.5 Methionine 5.0 Alliin 7.5 - Table 4 shows the results of the comparison of the concentrations of various antioxidants that will completely inhibit the proteolytic action of a 10 mM concentration of OH. that was performed in the same manner for antioxidants with an antioxidant action on OH.. The strongest antioxidant effect against oxidative degradation of protein by OH. was shown by the carotenoids astaxanthin and β-carotene, the polyphenols quercetin and catechins, and the caffeic acid analogues curcumin, ferulic acid, chlorogenic acid, and caffeic acid in that order, and among the items tested V.E. had the weakest antioxidant activity.
-
TABLE 4 Strength of OH•-Scavenging Action OH radical inhibitory Antioxidant concentration (μM) Astaxanthin 0.5 B-carotene 0.5 Quercetin 2.5 Catechins 2.5 Epigallocatechin gallate 2.5 Curcumin 2.5 Ferulic acid 2.5 Chlorogenic acid 3.0 Caffeic acid 4.0 Vitamin E 2500 - A microchannel (hereinafter, MC), which is a capillary model, is a device that measures hemorheology, i.e., the capability of blood to circulate through capillaries. Factors affecting hemorheology include meals, oxidative stress, etc. In the present invention the effects of the three active oxygen species produced in the body on the MC transit capability of human red blood cells were tested, and the effectiveness of various antioxidants in preventing the harmful effects of active oxygen were compared.
- For the test method, blood from healthy human volunteers was separated by a Ficoll-Paque centrifuge (made by Amersham-Pharmacia Biotech) into plasma, white blood cell, and a red blood cell fractions, and the MC transit time of each blood fraction was measured by an MC FAN KH-3A (
channel width 7 μm, MC Laboratory, Inc.) The results show that transit damage due to the three active oxygen species, ClO., OH., and ONOO., appeared in white blood cells (No. of nucleated cells: 2×105 cells/mL) and red blood cells (hematocrit 15%), but the transit capability of plasma (diluted 1:1) was unaffected (FIG. 3 ). Next, the effectiveness of various antioxidants in preventing the MC transit damage due to various active oxygen species was measured using red blood cells.FIG. 4 shows one example, and in this test an anserine-carnosine mixture (2.5 mM) from chicken extract as the ClO.-scavenger, EGCG (50 μM) as the OH.-scavenger, and V.C. (2.5 mM) as the ONOO.-scavenger were used. These three types were mixed together and used as the antioxidant mixture. As shown inFIG. 4 , the red blood cell transit damage due to each species of antioxidant was completely inhibited by the respective antioxidants, and the antioxidant mixture was effective in completely inhibiting the damage caused by each active oxygen species. - Using the diabetes model animal GK rats (Y. Ihara, et al. FEBS Letters, Vol. 473, p. 24-26, 2000), the effectiveness of single doses of various antioxidants and combined doses of antioxidants in lowering the level of glycated hemoglobin (HbAlc) in the blood was compared. It is known that there is a strong correlation between the mortality rate of patients with cardiovascular disease occurring concurrently with diabetes and the level of HbAlc in the blood; with a decrease of 0.1% in the HbAlc concentration, a drop of 5% in the mortality rate can be expected, and with a decrease of 0.2%, a drop of 10% can be expected (K. T. Khaw, et al. BMJ, Vol. 322, p. 1-6, 2001).
- As the ClO.-
scavenger 200 mg/kg of anserine-carnosine mixture derived from chicken extract, as the OH.-scavenger wheat grass extract (total content ofcaffeic acid analogues 10 mg/kg), as the ONOO.-scavenger 100 mg/kg of V.C., and a composition containing all three antioxidants were administered orally to the GK rats for 28 days, and the blood HbAlc levels were measured at the end of dosing. As shown inFIG. 5 , a decrease of 0.3% was seen with the ClO.-scavenger alone, a decrease of 0.2% was seen with the OH.-scavenger alone, a decrease of 0.3% was seen with the ONOO.-scavenger alone, and a decrease of 0.4% was seen with the composition that combined all three of the antioxidants; thus, the combination of the three species of antioxidants produced the best result in lowering the blood HbAlc concentration formed by the action of hyperglycemia and active oxygen. - It is known that, in the groups of the ingredients which have an antioxidant activity, there exist ingredients having some effect of lowering the level of cholesterol in the blood and that the functional mechanisms of the effect are various. As the mechanisms, for example, it seems that there exist the mechanism wherein the production of the energy from fat is facilitated to spend cholesterol in the body, the mechanism wherein the absorption of cholesterol via gut in the body is interrupted, the mechanism wherein the enzyme of synthesizing cholesterol is inhibited, and the mechanism wherein the ability to remove cholesterol by macrophage is accelerated and the like.
- It is known that the chlorogenic acid and ferulic acid which are caffeic acid analogue compounds used in the present invention also have an effect of lowering the level of cholesterol in the blood as an agent for scavenging OH. Radical (A. Herrera-Arellano et al., Phytomedicine, Vol. 11, p. 561-566, 2004; H. K. Kim et al., Clinica Chimica Acta, Vol. 327, p. 129-137, 2003).
- However, the effect of lowering the level of cholesterol in the body by the ferulic acid or chlorogenic acid which is ingested via oral administration is not elucidated and therefore, the inventors investigated whether the antioxidant component dosed via oral administration in the body has an effect of lowering the level of cholesterol in the blood.
- The antioxidant food drink prepared by the method of Example 5, that is, 50 mL of mango juice which contains 400 mg of the purified anserine-carnosine mixture derived from chicken extract as the ClO.-scavenger, 20 mg of the ferulic acid derived from rice bran as the OH.-scavenger, and 300 mg of vitamin C as ONOO.-scavenger was administered via oral to 17 male members of healthy volunteers for 4 days by 1 piece/day to measure the amount of lipids in the blood sample thereof collected before and after the administration.
- HDL cholesterol and neutral fat are measured as the lipids, and amount of LDL cholesterol was calculated according to the next formula, that is, the formula of LDL cholesterol=total cholesterol (HDL+neutral fat×0.2).
- The results obtained is shown in
FIG. 4-FIG . 6. With regard the value of the concentration of the total cholesterol in the blood of 12 members before the administration, the value was higher than 200 mg/dL before the administration, and the mean total cholesterol in the blood was lowered from 233.8±19.9 mg/dL to 219.3±24.2 mg/dL (p<0.05) after the administration. With regard to the value of LDL cholesterol of other 12 members before and after the administration, the value was higher than 120 mg/dL before the administration, and the mean LDL value in the blood was lowered from 149.0±16 mg/dL to 135.0±16.4 mg/dL (p<0.05) after the administration. With regard to the neutral fat, the value of cholesterol in the blood of 8 patients with high cholesterol value in the blood, the value was higher than 220 mg/dL before the administration, and the value thereof was lowered from 124.9±57.1 mg/dL to 91.6±29.4 mg/dL (p<0.05) after the administration. - (7) Effect of Agent Arranged with Three Ingredients
1) Inhibition Effects of Various Antioxidants on Ova Degradation by Three Active Oxygen species - The inhibitory action of each antioxidant toward Ova oxidative degradation by the three active oxygen species and agent arranged with three ingredients containing CoQ10 is shown in
FIG. 9 . - With respect to ClO radical (ClO.), the most strong inhibitory activity was seen with by the purified anserine-carnosine mixture from chicken extract, sulfur-containing amino acids and peptides, next, strong inhibitory activity was seen with by V.C., and CoQ10, however, did not inhibit the oxidative degradation of Ova. With respect to OH radical (OH.), 50 μM CoQ10 inhibited strongly the oxidative degradation of Ova and the inhibitory activity was not seen with by anserine-carnosine and vitamin C.
- With respect to ONOO radical (ONOO.), V.C. completely inhibited the oxidative degradation of Ova, and faint inhibitory activity was seen with by the anserine-carnosine mixture from chicken extract, sulfur-containing amino acids-peptides and CoQ10. Antioxidant agent arranged with three ingredients of 5 mM anserin-carnosine mixture derived from chicken extract, 50 μM CoQ10 and 5 mM V.C. almost completely inhibited the oxidative degradation of Ova by three types of the active oxygen species, as shown in
FIG. 9 . The inhibition effects of various antioxidants on the degradation of protein due to each active oxygen are summarized in Table 5 as “Inhibition Effects of Various Antioxidants on the Degradation of Protein due to each Active Oxygen”. -
TABLE 5 Inhibition Effects of Various Antioxidants on the Degradation of Protein due to each Active Oxygen ClO OH ONOO Antioxidant radical radical radical Anserine-carnosine (5 mM) 100 0 14 Reduced glutathione (5 mM) 100 18 29 Cysteine (5 mM) 100 15 22 N-acetyl-L-cysteine (5 mM) 100 20 20 Methionine (5 mM) 100 62 45 Vitamin C (5 mM) 67 18 100 CoQ10 (50 μM) 0 100 0 Antioxidant composition 100 100 100 with 3 ingredients * * Anserine-carnosine mixture from chicken extract (5 mM), CoQ10 (50 μM) and V.C. (5 mM) - A microchannel (MC), which is a capillary model, is a device that measures hemorheology, i.e., the capability of blood to circulate through capillaries. Factors effecting hemorheology include meals, oxidative stress, etc. In the present Example, the effects of the three active oxygen species produced in the body on the MC transit capability of human red blood cells were tested.
- For the test method, blood from healthy human volunteers was subjected a Ficoll-Pague centrifuge (made by Amersham-Pharmacia Biotech) to separate a red blood cell fraction, and the MC transit time of the red blood (final concentration of hematocrit is 10%) treated by various active oxygen species was measured by an MC FAN KH-3A (
channel width 7 μm, MC Laboratory, Inc.). The results show that transit damage due to the three active oxygen species, ClO., OH., and ONOO. appeared in the red blood cells. - With respect to ClO., anserine-carnosine mixture from chicken extract inhibited the MC transit damage, with respect to OH., CoQ10 inhibited the damage, and with respect to ONOO., V.C. inhibited the damage. In the case of antioxidative agent with 3 ingredients, the MC transit damage due to various radicals was completely inhibited (
FIG. 10 ). - 3) Effects of Improving Hemorheology in the Blood from Healthy Human Volunteers
- To the healthy male volunteers (58 years old, 35 years old and 29 years old), 50 mL of juice drink containing 400 mg of anserine-carnosine mixture from chicken extract, 300 mg of vitamin C and 20 mg of CoQ10 was administracted via oral for 10 days by one piece/day to measure the effect of improving the liquidity of the blood samples of the volunteers before and after the administration by measuring the MC transit time by using the above MC FAN KH-3A. As the results, the mean MC transit time before the administration was 55.1 seconds, and the mean MC transit time after the administration was improved to 46.6 seconds (
FIG. 11 ). - The present invention provides the following advantages:
- (1) It divides the active oxygen species produced in the body into three groups and provides antioxidants that act effectively on each group;
- (2) It identifies and formulates antioxidants against the OH. system produced from oxygen gas, and the chlorine system and nitric oxide system produced from white blood cells; and
- (3) It enables the provision of antioxidant food products that are effective in suppressing the onset of diseases associated with aging and lifestyle.
-
FIG. 1 shows the inhibitory effect of various antioxidants on ovalbumin degradation by active oxygen. A represents oxygen degradation by 10 mM of the ClO radical, B represents oxygen degradation by 10 mM of the OH radical, and C represents oxygen degradation by the ONOO radical. The symbols used in each panel for the added sample materials are as follows: R is untreated ovalbumin, C is oxidatively degraded control ovalbumin, 1 is the purified anserine-carnosine mixture, 2 is vitamin C, 3 is vitamin E, 4 is astaxanthin, 5 is β-carotene, 6 is catechin, 7 is quercetin, 8 is epigallocatechin gallate (EGCG), 9 is curcumin, 10 is chlorogenic acid, and 11 is ferulic acid (the concentrations are shown in Table 1); -
FIG. 2 shows the inhibitory effect of various natural ingredients on the degradation of ovalbumin by active oxygen. A represents oxidative degradation by 10 mM of the ClO radical, B represents oxidative degradation by 10 mM of the OH radical and C represents oxidative degradation by the ONOO radical. The symbols used in each panel are as follows: R is untreated ovalbumin, C is oxidatively degraded control ovalbumin, 1 is chicken extract, 2 is lemon juice, 3 is rice bran extract, 4 is salmon extract, 5 is carrot extract, 6 is mulberry leaf extract, 7 is onion extract, 8 is tea leaf extract, 9 is tumeric extract, 10 is cabbage extract, and 11 is wheat grass extract (the concentrations are shown in Table 2); -
FIG. 3 shows the microchannel transit capability of human blood constituents. A is blood treated with ClO radical, B is blood treated with OH radical and C is blood treated with ONOO radical. The bars in the graph from left to right represent plasma, white blood cells, and red blood cells; -
FIG. 4 shows the effect of each active oxygen species on human red blood cells and the effect of each species of antioxidant on microchannel transit capability. A is blood treated with ClO radical, B is blood treated with OH radical, and C is blood treated with ONOO radical. The bars in the graph from left to right represent control, addition of ClO.-scavenger, addition of OH.-scavenger, addition of ONOO.-scavenger, and the mixture of three species of antioxidants; -
FIG. 5 shows the effect of various species of antioxidants in decreasing the blood HbAlc concentration in diabetes model GK rats; -
FIG. 6 shows concentration of the total cholesterol in each blood samples of 12 members of healthy volunteers; -
FIG. 7 shows concentration of LDL cholesterol in each blood samples of 12 members of healthy volunteers; -
FIG. 8 shows concentration of the neutral fat in blood samples of 8 members with high cholesterol value; -
FIG. 9 shows the inhibition effect on the degradation of ovoalbumin due to active oxygen species by each antioxidant. A is the oxidative degradation by 10 mM of ClO radical, B is that by 10 mM of OH radical and C is that by ONOO radical. In each panel, R is untreated ovoalbumin, C is oxidatively degradated ovoalbumin as blank, 1 is 5 mM of anserine-carnosine mixture from chicken extract, 2 is 5 mM of vitamin C, 3 is 50 μM of CoQ10, and 4 is antioxidant arranged with the above three ingredients; -
FIG. 10 shows effectiveness of antioxidants in preventing damage by active oxygen on the microchannel transit capability of human red blood cells. Pannel A is the oxidative degradation by 10 mM of 010 radical, panel B is that by 10 mM of Oh radical, panel C is that by 5 mM of ONOO radical. Each panel shows, from left to right, a blank without any antioxidants, added with anserine-carnosine from chicken extract, added with vitamin C, added with CoQ10, and added with these 3 ingredients respectively; and -
FIG. 11 shows effect on the improvement of the liquidity of blood of healthy volunteers. - Next, the present invention will be specifically described based on examples, but the present invention is not intended to be limited to the examples below.
- A 20% solid concentrate was prepared by vacuum concentration of 40 L of chicken extract obtained by hot water extraction from 10 kg of whole chicken carcasses. The content of anserine-carnosine mixture in this concentrated chicken extract was 140 mg/g per solid substance. To 1200 g of the concentrated chicken extract were added 16.8 g of V.C. (food additive) and 840 g of concentrated wheat grass extract prepared by obtaining an extract by hot water extraction from wheat grass and concentrating it to contain 10% solids and a 0.2% caffeic acid analogues; 60 g of non-digestible dextrin was added and mixed; and spray drying was performed to obtain approximately 400 g of antioxidant composition powder containing an ClO.-scavenger, OH.-scavenger, and ONOO.-scavenger. The final content was 84 mg of anserine-carnosine, 42 mg of V.C., and 4 mg of caffeic acid analogues per 1 g of powder. It was confirmed that this powder exhibits a blood HbAlc level lowering effect in tests using the aforementioned diabetes model rats.
- To 5 kg of gutted and boned salmon was added 15 kg of water, and the mixture was boiled for 3 hr at 100° C., and then homogenized in a mixer; a 0.2% concentration of proteolytic enzyme was added, and hydrolysis was performed for 4 hr at 45° C. to prepare a red salmon paste. To 20 kg of the red salmon paste was added 1 kg of the concentrated whole chicken extract from Example 1, 60 g of sodium V.C., 10 g of green tea extract powder (
catechin content 20%), 40 g of seasoning liquid, and 100 g of dextrin; and spray drying was performed to prepare approximately 2 kg of salmon extract containing the antioxidant mixture. The content was 50 mg of anserine-carnosine, 25 mg of V.C., 1 mg of astaxanthin as total carotenoid, and 10 mg of catechins per 1 g of powder. A 1% solution of this powder completely inhibited the proteolytic action of the three active oxygen species. - To 10 kg of pork was added 30 kg of water and the mixture was heated for 2 hr at 100° C. to obtain a liquid extract; the extract was filtered to remove precipitates and vacuum concentrated to prepare approximately 4 g of concentrated pork extract containing 10% solids. To this was added 1 kg of onion extract (
solid content 10%), 100 g of sodium V.C., and 100 g of wheat grass extract powder (caffeic acid analogue content 1.5%); spray drying was then performed to prepare approximately 600 g of pork extract powder for stew containing the antioxidant mixture. The content was 85 mg of anserine-carnosine mixture, 140 mg V.C., and 1 mg of quercetin and 2 mg of the caffeic acid analogue ferulic acid as polyphenols per 1 g of powder. A 1% aqueous solution of this powder completely inhibited the proteolytic action of the three active oxygen species. - Chicken extract was filtered through a 3,000 molecular weight fraction ultrafiltration membrane (SEP-3013, Asahi Kasei Corporation), and the filtrate that passed through the ultrafiltration membrane was concentrated to purify the anserine-carnosine mixture using a chromatograph packed with Dowex 50Wx8 cationic exchange resin. Separately, rice bran extract obtained from the hot water extraction of rice bran was added to activated carbon, and decolorization, filtering, and concentration to a solid content of 20% were performed to prepare a concentrated rice bran extract containing caffeic acid analogues. In addition, grapefruit were placed in a mixer and after mixing, the fruit juice obtained thereby was filtered to remove insolubles. To 100 mL of grapefruit juice was added 500 mg of the aforementioned purified anserine-carnosine mixture, 10 mL of rice bran extract (
ferulic acid content 30 mg), 200 mg of V.C., 1 g of sweetener, and a suitable amount of natural grapefruit flavoring to prepare a soft drink containing an antioxidant mixture. A 10-fold aqueous dilution of the fruit drink completely inhibited the proteolytic action of the three active oxygen species. - To 50 mL of mango juice was added, 400 mg of the purified anserine-carnosine mixture prepared by the method of the example 4, 20 mg of the purified ferulic acid extracted from rice bran (made by Chikuno Rice Fine Chemicals) and 300 mg of the vitamin C (food additive) to prepare 3000 pieces of antioxidant food drinks.
- To 50 mL of the mango juice (60%), 400 mg of anserine-carnosine mixture from chicken extract, 300 mg of V.C. (food additive) and 0.2 g (20 mg as CoQ10) of water soluble CoQ10 emulsion (made by Yokohama oils and fats) were added to procude juice drink containing the above three antioxidative ingredients. It was observed that this juice drink, as shown in the above text example (7), had the effect of improving the liquidity of the blood samples of the healthy volunteers.
- The chicken extract obtained by boiling-water extraction of hole chicken was concentrated, freeze-dried to produce chicken extract powder containing 10% of anserine-carnosine. To 2.0 g of the chicken extract powder, 150 mg of V.C. (food additive), 200 mg (10 mg as CoQ10) of CoQ10 (made by Nisshin pharma), further, 80 g of corn powder, 1 g of onion powder and 1 g of seasoning were added to produce instant corn soup powder. This corn soup powder 12.6 g was dissolved into 100 mL of 80° C. hot water to obtain corn potage soup enriched with the antioxidant composition.
- By the results of the test, it was revealed that this soup showed the effect of inhibiting the oxidative degradation of the protein by the three active oxygen species produced in the body.
- As described in detail above, the present invention relates to an antioxidant composition, and antioxidant compositions that act effectively against a wide range of active oxygen species can be provided thereby. In the past foods containing a single antioxidant have been widely used to prevent aging and prevent lifestyle related diseases. For example, there are various diseases wherein arteriosclerosis and hypertension, cancer, diabetes and various diseases accompanied with diabetes. However, in clinical studies of antioxidants on the prevention of lifestyle diseases and aging that have been conducted in the past, satisfactory results have not always been obtained. There are many possible causes, but first, the clinical effectiveness obtained in vitro and by forced administration to animals may not be realized in humans due to problems with gastrointestinal absorption and distribution throughout the body when taken orally. Second, the active oxygen in the body that causes aging and lifestyle diseases is not a single entity and various species are produced depending on the physiological conditions and lifestyles of human beings. In the past the strength of antioxidant activity has been evaluated using active oxygen that has only meager correlation with the active oxygen produced in the body, and the ranking of intensity has been stipulated using those criteria. However, as verified in the tests of the present invention, the actions of various species of antioxidant at physiologically relevant concentrations are specific with respect to each active oxygen species, and it has become clear that substances that have been evaluated in the past as having weak antioxidant activity demonstrate powerful antioxidant activity against a specific active oxygen species, and conversely, substances that have been evaluated as having strong antioxidant activity actually have only weak activity against some active oxygen species. Based on these findings, with foods having a single antioxidant as the main ingredient it has been impossible to satisfactorily prevent various diseases that emerge due to various active oxygen species produced in the body.
- In the present invention the active oxygen species produced in the body are divided into three groups, and antioxidants for the active oxygen species of the OH. system produced from oxygen gas, and of the chlorine system and nitric oxide system produced by white blood cells are identified. As a result, the present invention has revealed that peptides and sulfur-containing amino acids that constitute peptides have a strong antioxidant action against the active oxygen of the chlorine system, carotenoids and polyphenols from plans and substances that have a hydrophobic group such as phenols have a strong antioxidant action against the active oxygen of the OH. system, and vitamin C, etc., have a strong antioxidant action against the active oxygen of the nitric oxide system. From these findings it is important that an antioxidant composition act effectively against a wide range of active oxygen species, and in fact, because it has been recognized that the combined use of antioxidants markedly inhibits the production of ultimately glycated products in the body that occur due to oxidative damage, it is possible to provide antioxidant foods that are even more effective in preventing the emergence of aging and lifestyle disease than in the past. In addition, it is possible to manufacture antioxidant food ingredients that are even more effective by combining natural ingredients that contain these antioxidant constituents.
Claims (17)
1. An antioxidant composition comprising in the following proportions:
at least 20 mg of vitamin C (L-ascorbic acid or L-ascorbate)
at least 2 mg of caffeic acid analogue compound(s),
at least 10 mg of polyphenyol compound(s) or at least 1.5 mg of carotenoid compound(s) and
100 mg of histidine-containing dipeptide, or sulfur-containing amino acids or analogues thereof.
2. The antioxidant composition according to claim 1 , wherein the histidine-containing dipeptide of the agent for scavenging hypochlorite active oxygen is a mixture of anserine and carnosine, and the sulfur-containing amino acid or analogue thereof is one or more species of reduced glutathione, cysteine, acetylcysteine, or methionine, or alliin obtained from extracts of plants of the Allium or Brassica families.
3. The antioxidant composition according to claim 1 , comprising a caffeic acid analogue extracted from plants of the wheat or poaceae families.
4. The antioxidant composition according to claim 1 , comprising a polyphenol compound that is catechin extracted from mulberry leaves or tea leaves, and/or quercetin extracted from the Allium family.
5. The antioxidant composition according to claim 1 , comprising a carotenoid compound that is astaxanthin extracted from fish meat or algae, and/or β-carotene extracted from plants selected from the group consisting of ashitaba (Angelica keiskei), pumpkin, carrot, mugwort, perilla, or kale.
6. The antioxidant composition according to claim 1 wherein at least 20 mg of vitamin C (L-ascorbic acid or L-ascorbate) and at least 2 mg of caffeic acid analogue compound(s) are combined with 100 mg of the histidine-containing dipeptide, or at least one sulfur-containing amino acid.
7. The antioxidant composition according to claim 1 , wherein histidine-containing dipeptide is a mixture of anserine and carnosine, and the caffeic acid analogue compound(s) is at least one of ferulic acid, chlorogenic acid, cinnamic acid, or caffeic acid.
8. The antioxidant composition according to claim 1 , comprising at least 20 mg of vitamin C (L-ascorbic acid or L-ascorbate) and at least 2 mg of ubiquinone in combination with 100 mg of the histidine-containing dipeptide, or in combination with one or more sulfur-containing amino acids.
9. A food to which the antioxidant composition defined in claim 1 has been added.
10. A food to which the antioxidant composition of claim 6 has been added.
11. A food to which the antioxidant composition defined in claim 8 has been added.
12. The antioxidant composition of claim 1 that does not contain vitamin E.
13. The antioxidant composition of claim 1 that contains at least 10 mg of polyphenyol compound(s) per 100 mg of histidine-containing dipeptide, or sulfur-containing amino acids or analogues thereof.
14. The antioxidant composition of claim 1 that contains at least 1.5 mg of a carotenoid compound(s) per 100 mg of histidine-containing dipeptide, or sulfur-containing amino acids or analogues thereof.
15. The antioxidant composition of claim 1 that contains at least one sulfur-containing amino acid that is not anserine-carnosine.
16. A method for reducing or suppressing active oxygen species of a subject comprising administering the antioxidant composition of claim 1 to a subject in need thereof, wherein said composition educes or suppresses hypochlorite radicals, hydroxyl radicals, and peroxynitrite radicals of said subject.
17. The method of claim 16 , wherein said composition is orally administered.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/753,481 US20100240599A1 (en) | 2004-04-30 | 2010-04-02 | Antioxidant constituents |
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004136934 | 2004-04-30 | ||
JP2004-136934 | 2004-04-30 | ||
JP2005085028A JP4971597B2 (en) | 2005-03-23 | 2005-03-23 | Antioxidant composition |
JP2005-085028 | 2005-03-23 | ||
JP2005125601A JP5089025B2 (en) | 2004-04-30 | 2005-04-22 | Antioxidant composition |
JP2005-125601 | 2005-04-22 | ||
US11/118,368 US7727961B2 (en) | 2004-04-30 | 2005-05-02 | Antioxidant constituents |
US12/753,481 US20100240599A1 (en) | 2004-04-30 | 2010-04-02 | Antioxidant constituents |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/118,368 Continuation US7727961B2 (en) | 2004-04-30 | 2005-05-02 | Antioxidant constituents |
Publications (1)
Publication Number | Publication Date |
---|---|
US20100240599A1 true US20100240599A1 (en) | 2010-09-23 |
Family
ID=35240174
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/118,368 Active 2028-01-18 US7727961B2 (en) | 2004-04-30 | 2005-05-02 | Antioxidant constituents |
US12/753,481 Abandoned US20100240599A1 (en) | 2004-04-30 | 2010-04-02 | Antioxidant constituents |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/118,368 Active 2028-01-18 US7727961B2 (en) | 2004-04-30 | 2005-05-02 | Antioxidant constituents |
Country Status (2)
Country | Link |
---|---|
US (2) | US7727961B2 (en) |
TW (1) | TWI307267B (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20100014799A (en) * | 2007-01-17 | 2010-02-11 | 엔베쎄 뉴트라쇠틱 비지니스 컨썰팅 | Anti-oxidant dietary composition containing fruits and vegetables, method for preparing the same and use of the composition |
AU2010282674A1 (en) * | 2009-08-10 | 2012-02-23 | Stokely-Van Camp, Inc. | Method for suspending a flavonoid in a beverage |
DE102009058325A1 (en) * | 2009-12-15 | 2011-06-16 | Henning Vollert | Extract of a plant of Brassica, useful for increasing antioxidant activity of epithelial tissue e.g. epithelial tissue of skin or preventing and treating eye diseases e.g. macular degeneration or cataract and preventing eating disorders |
KR101405558B1 (en) * | 2011-09-22 | 2014-06-16 | 주식회사 바이오에프디엔씨 | Caffeoyl-alpha-neo-endorphin Peptide Derivatives and its usage as anti-itching and anti-atopic dermatitis agent |
CN115558692B (en) * | 2022-12-06 | 2023-04-28 | 蓝鲲海洋生物科技(烟台)有限公司 | Method for preparing tuna peptide rich in anserine and glutathione |
CN116035183A (en) * | 2023-02-14 | 2023-05-02 | 昆明白鸥微藻技术有限公司 | Antioxidation and color-increasing method for shrimp and crab products |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5977073A (en) * | 1991-06-06 | 1999-11-02 | Life Sciences' Technologies, Inc. | Nutrient composition for treatment of immune disorders |
US6048846A (en) * | 1998-02-26 | 2000-04-11 | Cochran; Timothy M. | Compositions used in human treatment |
US6210701B1 (en) * | 1999-04-30 | 2001-04-03 | Healthcomm International, Inc. | Medical food for treating inflammation-related diseases |
US20010053356A1 (en) * | 2000-03-20 | 2001-12-20 | Ahmed Mousa | Garlic ingredients and antioxidants in the prevention and treatment of vascular-related disorders and pathological angiogenesis-mediated disorders |
US6352712B1 (en) * | 1999-04-30 | 2002-03-05 | Daniel O. Lukaczer | Dietary supplements for treating fatigue-related syndromes |
US20040121024A1 (en) * | 2002-12-19 | 2004-06-24 | Gorsek Wayne F. | Composition for the treatment and prevention of osteoarthritis, rheumatoid arthritis and improved joint function |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4833502B2 (en) | 2003-01-31 | 2011-12-07 | 東海物産株式会社 | Antioxidant composition |
-
2005
- 2005-05-02 TW TW094114124A patent/TWI307267B/en active
- 2005-05-02 US US11/118,368 patent/US7727961B2/en active Active
-
2010
- 2010-04-02 US US12/753,481 patent/US20100240599A1/en not_active Abandoned
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5977073A (en) * | 1991-06-06 | 1999-11-02 | Life Sciences' Technologies, Inc. | Nutrient composition for treatment of immune disorders |
US6048846A (en) * | 1998-02-26 | 2000-04-11 | Cochran; Timothy M. | Compositions used in human treatment |
US6210701B1 (en) * | 1999-04-30 | 2001-04-03 | Healthcomm International, Inc. | Medical food for treating inflammation-related diseases |
US6352712B1 (en) * | 1999-04-30 | 2002-03-05 | Daniel O. Lukaczer | Dietary supplements for treating fatigue-related syndromes |
US20010053356A1 (en) * | 2000-03-20 | 2001-12-20 | Ahmed Mousa | Garlic ingredients and antioxidants in the prevention and treatment of vascular-related disorders and pathological angiogenesis-mediated disorders |
US20040121024A1 (en) * | 2002-12-19 | 2004-06-24 | Gorsek Wayne F. | Composition for the treatment and prevention of osteoarthritis, rheumatoid arthritis and improved joint function |
Non-Patent Citations (1)
Title |
---|
Candalish et al (Biomed Environ Sci 9:117-123, 1996) * |
Also Published As
Publication number | Publication date |
---|---|
US20050250703A1 (en) | 2005-11-10 |
US7727961B2 (en) | 2010-06-01 |
TW200605797A (en) | 2006-02-16 |
TWI307267B (en) | 2009-03-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5089025B2 (en) | Antioxidant composition | |
Althunibat et al. | Protective role of Punica granatum L. peel extract against oxidative damage in experimental diabetic rats | |
Rainha et al. | Antioxidant properties, total phenolic, total carotenoid and chlorophyll content of anatomical parts of Hypericum foliosum | |
US20100240599A1 (en) | Antioxidant constituents | |
JPWO2006014028A1 (en) | Sweet potato stem and leaf extract and use thereof | |
US20150201661A1 (en) | Bamboo extracts, compositions and uses thereof | |
CA2507987C (en) | A vegetable composition having blood enhancing properties | |
KR20190055942A (en) | Composition for fishy smell deodorant | |
EP2752195A1 (en) | Grape extract, nutritional supplement comprising grape extract, and the use thereof as a functional ingredient | |
TWI669068B (en) | Antioxidant dietary supplement compositions | |
Kupradinun et al. | Anticlastogenic and anticarcinogenic potential of Thai bitter: gourd fruits | |
JP4833502B2 (en) | Antioxidant composition | |
Elmaadawy | Phyto-extracts applied in beef meatballs ameliorates hyperglycemia and its complications in alloxan-induced diabetic rats | |
JP2003267992A (en) | Antioxidant, aging prevention and/or anticancer agent | |
KR20190135438A (en) | Antioxidant composition comprising mixture of the extract of Chunggukjang and Modordica charantia | |
EP3247323B1 (en) | Chlorophyll composition | |
JP2006347975A (en) | Oral composition for cardiovascular disease prophylaxis and amelioration | |
JP7376482B2 (en) | Deodorant composition for suppressing body odor derived from the body | |
Johnson et al. | Comparative effect of daily administration of allium sativum and allium cepa extracts on alloxan induced diabetic rats | |
JP2006296378A (en) | Seasoning composition containing pine bark extract | |
JP2006265161A (en) | Antioxidant composition | |
اسحق et al. | Evaluation of Therapeutic Effect of Cantaloupe, Grape and Pumpkin Seeds on Cisplatin Induced Nephrotoxicity in Rats | |
JP2004107314A (en) | Oral administration formulation for antioxidation | |
Marwa et al. | Using some beetroot products to improve some parameters in anemic rats induced by phenylhydrazine | |
JP7321017B2 (en) | functional food |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |